Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
1. 2024 begins with promising M&A activity in pharmaceuticals. 2. Johnson & Johnson's acquisition hints at larger industry trends. 3. Major pharma faces urgent need for new products amid patent expirations. 4. GSK participated in several deals recently, reflecting active M&A involvement. 5. Upcoming policy changes may influence corporate financial strategies.